Health
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health
Opportunity #: RFA-NS-26-001
Award Ceiling
N/A
Award Floor
N/A
Close Date
Nov 10, 2026
35 days leftTotal Funding
$40.0M
Expected Awards
4
Posted Date
May 4, 2026
Cost Sharing Required
No
Grants.gov ID
360400
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Eligible Applicants
State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and state-controlled institutions of higher education; Federally recognized Native American tribal governments; Public housing authorities or Indian housing authorities; Native American tribal organizations other than governments; Nonprofits with 501(c)(3) status; Nonprofits without 501(c)(3) status; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Other applicants
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.